Graduate Student, School of Pharmacy, University of Waterloo, Waterloo, ON.
Associate Professor, School of Pharmacy, University of Waterloo, Waterloo, ON.
Healthc Policy. 2021 Feb;16(3):89-105. doi: 10.12927/hcpol.2021.26430.
In Canada, chimeric antigen receptor (CAR) T-cell therapy was recommended for funding for the treatment of select hematological cancers. Canadian hospitals have limited experience and capacity in administrating this therapy. We conducted a qualitative interview-based study with stakeholders in Canada. Questions were asked related to the development, administration, implementation and logistical planning of CAR T-cell therapy. Results were summarized into four main themes: (i) novel; (ii) patient characteristics and the delivery of care; (iii) processes from "bench-to-bedside"; and (iv) the future state, including both challenges and recommendations to ensure sustainability. Valuable perspectives from stakeholders highlight some of the unique challenges to implementing a highly personalized and expensive-to-deliver therapy.
在加拿大，嵌合抗原受体 (CAR) T 细胞疗法被推荐用于资助某些血液系统癌症的治疗。加拿大医院在管理这种疗法方面经验有限，能力有限。我们对加拿大的利益相关者进行了一项基于定性访谈的研究。问题涉及 CAR T 细胞疗法的开发、管理、实施和后勤规划。结果总结为四个主要主题：(i) 新颖性；(ii) 患者特征和护理提供；(iii) “从实验室到病床”的过程；以及 (iv) 未来状态，包括确保可持续性的挑战和建议。利益相关者的宝贵观点强调了实施这种高度个性化和昂贵的治疗方法所面临的一些独特挑战。
